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Background: Circulating tumor cells (CTCs) are associated with inferior prognosis in metastatic breast cancer
(MBC). We hypothesized that the relationship between CTCs and disease subtype would provide a better
understanding of the clinical and biologic behavior of MBC.
Patients and methods: We retrospectively analyzed 517 MBC patients treated at a single institution. Subtypes
of primary tumors were analyzed by immunohistochemical (IHC) or fluorescent in situ hybridization analyses and CTCs
were enumerated by CellSearch at starting a new therapy. Overall survival (OS) and progression-free survival
durations for each IHC subtype were determined.
Results: At a median follow-up of 24.6 months, 276 of 517 (53%) patients had died. The median OS for patients with
<5 and ‡5 CTCs were 32.4 and 18.3 months, respectively (P < 0.001). Except in HER2+ patients, the prognostic value
of CTCs was independent of disease subtype and disease site.
Conclusions: In this large retrospective study, CTCs were strongly predictive of survival in all MBC subtypes except
HER2+ patients who had been treated with targeted therapy. Our results clearly demonstrate the value of enumerating
CTCs in MBC and strongly suggest an interesting biological implication in the HER2+ subset of patients that need
to be further explored.
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introduction
Breast cancer is the most common cancer among women in the
United States, with 194 280 new cases of invasive breast cancer
and 40 610 confirmed breast cancer deaths during 2009 [1].
Only 5.6% of patients with newly diagnosed disease will present
with advanced or metastatic breast cancer (MBC) [1].
However, 40% of patients initially presenting with localized
disease eventually experience progression to MBC and die of
their disease [2]. Recent evidence suggests that MBC is not
a uniform disease and that breast cancer subtypes are associated
with significant differences in distant spread patterns,
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independent of conventional clinical–pathologic variables [3].
Metastatic spread models demonstrate complex interactions of
‘seed and soil’ factors involving tumor intravasation, traversing
the peripheral circulation, extravasation from the periphery,
invasion, proliferation, and angiogenesis [4]. Detecting
circulating tumor cells (CTCs) may provide a better
understanding of the biological behavior of tumor changes
during the metastatic process because they may represent the
seed from primary tumor to metastatic lesion.
The detection of CTCs, as carried out using the US Food and
Drug Administration-cleared CellSearch system (Veridex,
LLC, Warren, NJ) before the initiation of new systemic
treatment, is a strong independent predictor of overall survival
(OS) and progression-free survival (PFS) in MBC [5–18].
Moreover, the CTC enumeration is strongly correlated with
radiographic determination of disease progression in patients
undergoing chemotherapy or endocrine therapy [19]. Recent
data suggest that the CTC phenotype and immunopathologic
characteristics may be discordant among the primary tumor,
metastatic deposits, and CTCs [20–23]. These data suggest the
existence of an independent CTC phenotype that is associated
with adverse prognosis and treatment effectiveness. Therefore,
we determined the clinical value of the CTC count according to
immunohistochemically defined subtypes, specific metastatic
disease sites, and defined standard therapies to validate the
prognostic information of CTCs within defined subset of disease.
Our study objectives were to confirm the differences in
clinical behavior among subtypes of breast cancer and define
the prognostic role of CTCs in relation to those factors. An
independent association would suggest that these cells play
a critical role in the metastatic process, that additional
molecular characterization is needed, and that CTC-targeted
therapies would be effective. To our knowledge, this is the
largest retrospective study of CTCs in MBC patients.
patients and methods
patient population
We searched our prospectively maintained laboratory database to
identify patients with MBC who had undergone standard baseline CTC
evaluation at The University of Texas M. D. Anderson Cancer Center
(Houston, TX) and had been treated between September 2002 and
November 2009. For all patients, a baseline CTC evaluation had been
carried out using the CellSearch within 30 days before starting a new
line of therapy. Moreover, to be included in our study, patients were
required to have clinical and radiologic evidence of MBC, with
measurable or evaluable disease, before initiating new therapy. All
patients had undergone imaging studies, laboratory evaluations, and
treatment planning at our institution. The institutional review board at
the University of Texas M. D. Anderson Cancer Center approved the
study (DR10-0227) and granted a waiver of informed consent,
considering the retrospective nature of the study.
immunohistopathologic findings and staging definition
Histological type and grade of invasive disease were coded according to the
World Health Organization classification system [24] and modified Black
nuclear grading system, respectively [25]. Consistent with institutional
standard, all specimens from within and without the institution were
analyzed by a pathologist at this institution. The method used to determine
hormone receptor (HR) status depended on the year of primary diagnosis.
For specimens obtained before 1993 (n = 13), estrogen and progesterone
receptors (ER and PR) status were determined using the dextran-coated
charcoal ligand-binding method. For specimens obtained after 1993,
immunohistochemical (IHC) staining with monoclonal antibodies 6F11
and 1A6 (Novacastra Laboratories, Ltd., Burlingame, CA) were used to
determine ER and PR status, respectively, on 4-lm paraffin-embedded
tissue. Patients with at least one positive HR (ER or PR ‡ 1%) were
considered HR+. HER2 status was determined using IHC (AB8 Neo
Markers) and FISH using the PathVysion HER-2/neu DNA Probe Kit
(LSI HER-2/neu SpectrumOrange/CEP17 SpectrumGreen). Specimens
scored as IHC 0, 1+, 2+ and no gene amplification by FISH (HER2/CEP17
signal ratio <2) were considered HER2 constitutive or negative.
Specimens scored as IHC 3+ or demonstrating gene amplification by
FISH were considered HER2+ or amplified. Triple-receptor negative
(TN) status was assigned to patients whose tumors were negative for ER,
PR, and HER2. In our study, we refer at IHC breast cancer subtypes as
follows: HR+/HER22, HR+/HER2+, HR2/HER22, and TN breast
cancer.
Metastatic sites were evaluated at the time of phlebotomy and characterized
on the basis of radiologic imaging findings and patients’ cancer history.
Visceral and non-visceral metastases were defined in a previous paper [6].
CTC count
CTCs were isolated and counted using the USA Food and Drug
Administration-cleared CellSearch technology (Veridex, LLC) as
previously reported [26]. Briefly, 7.5 ml of peripheral blood were collected
in CellSave tubes and incubated with anti-EpCAM-coated ferrous
particles to enrich for epithelial cells. The EpCAM-enriched cell fraction
was labeled with fluorescent nucleic acid dye 4,2-diamidino-2-phenylindole
dihydrochloride (DAPI), stained with antibodies to identify cytoplasmic
cytokeratins (CKs)-8, CK18 and CK19 as well as with anti-CD45 to identify
contaminating leukocytes. CTCs were identified and counted using the
CellSpotter, a semi-automated fluorescence-based microscopy system that
permits computer-generated reconstruction of cellular digitized images.
CTCs were identified as cells with the appropriate morphologic
characteristics: CK positive, DAPI positive, and CD45 negative. Technical
details of the CellSearch and CellSpotter systems, including accuracy,
precision, linearity, and reproducibility, have been described previously
[26]. All CTC assessments were carried out in a central laboratory (M. D.
Anderson Cancer Center, Houston, TX) by an experienced operator and the
digitized images of CTCs were reviewed and validated by a board-certified
pathologist. A cut-off of five CTCs per 7.5 ml of blood was chosen to
distinguish patients with an unfavorable prognosis from patients with
a favorable prognosis [5].
statistical analysis
Differences among patient characteristics between CTC groups (<5 or ‡5)
were tested using Fisher’s exact test or Pearson chi-square test. OS duration
was defined as the time of basal blood draw for CTCs to the date of death. All
living patients were censored at the last follow-up date. PFS duration, defined
as the time of basal blood draw to documentation of disease progression
(according to RECIST), and all clinical data available in M. D. Anderson’s
electronic medical records (ClinicStation) were independently verified by two
physicians (AG and MG). All data, such as survival and treatments, were
collected from patients’ records. Patients without progressive disease were
censored at the last follow-up date. Kaplan–Meier plots were compared using
the log-rank test. To evaluate the interaction between IHC subtypes of disease
and CTC count, we quantified the heterogeneity between subgroups (CTCs
<5 and ‡5) with the Higgins’ I2 index [27]. A backward stepwise Cox
regression test was used to model and assess the relationship among PFS, OS,
and CTC value. After adjusting for clinical variables, we removed bone
metastasis and performance status from the analysis because they were not
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statistically significant. In the final regression model, we considered CTC
number (<5 versus ‡5), HR (positive versus negative), HER2 (positive versus
negative), visceral metastasis (yes versus no), and number of metastatic sites (1
versus 2 versus ‡3). All statistical test analyses were two-sided, and P values
<0.05 were considered statistically significant. Analyses were carried out using
SPSS 17 statistical software (SPSS, Inc. Somers, NY).
results
patient characteristics
This study was restricted to a cohort of 517 MBC patients.
Table 1 shows patients’ pathological and clinical characteristics
according to CTC count. Two hundred and six (40%) patients
had ‡5 CTCs at baseline blood draw, and 311 (60%) had <5
CTCs. The distribution of tumor by subgroup classification was
as follows: (56.4%) had HR+/HER22, 9.7% had HR+/HER2+,
9.9% had HR2/HER2+, and 24% had HR2/HER22. A larger
proportion of HR+/HER22 patients had ‡5 CTCs than did
patients with other subtypes of tumor (P = 0.024). No
significant differences in CTC counts were found within the
other subtypes of tumor. CTCs in patients with visceral
metastasis (62%) were equally distributed between patients
with <5 CTCs and those with ‡5 CTCs. However, 80% of
patients with ‡5 CTCs presented with bone involvement versus
56% of patients with fewer than 5 CTCs (P < 0.001). The
number of metastatic sites was associated with a high CTCs
count (P = 0.02); this difference was not more significant after
adjusting for bone metastasis (data not shown).
administered treatments
Approximately 46% of patients had undergone first-line
treatment of newly diagnosed MBC. Chemotherapy alone,
chemotherapy plus bevacizumab, anti-HER2 combination
treatment, hormonal treatment, or other investigational
treatments were administered in 48%, 13%, 15%, and 19% or
5% of cases, respectively (supplemental Table 1, available at
Annals of Oncology online). Among the 292 ER+/HER22
patients, 92 (32%) had undergone hormonal treatment. Of the
101 HER2+ patients, 84 (83%) had received trastuzumab or
lapatinib. Seventy-six percent of ER+/HER2+ patients and 90%
of ER2/HER2+ patients had received anti-HER2 agents.
overall outcome and CTCs
At a median follow-up period of 24.6 months, 456 (88%) of
517 patients had showed progression of disease and 276 (53%)
patients had died. In the largest group of patients (HR+/
HER22, n = 292), the median OS duration was 27.3 months
[95% confidence interval (CI) 23.6–30.9 months] and PFS was
6.4 months (95% CI 5.6–7.3 months). In HR+/HER2+ patients
(n = 50), the median OS duration was not yet reached and PFS
was 7.6 months (95% CI 5.3–9.8); in HR2/HER2+ patients
(n = 51), the median OS was 26 months (95% CI 18.3–33.6
months) and PFS was 7.5 months (95% CI 5.4–9.7 months). In
TN patients (n = 124), the median OS duration was 15.8
months (95% CI 13.2–18.4 months) and PFS was 4.9 months
(95% CI 4.2–5.5 months) (Figure 1A and B). One hundred and
forty-one (68%) of the 206 patients with ‡5 CTCs had died by
the time of this analysis, compared with 135 (43%) of 311 with
<5 CTCs. As shown in Figure 1C and D, shorter median OS and
PFS durations were observed in patients with ‡5 CTCs than in
those with <5 CTCs (OS, 18.3 versus 32.4 months, P < 0.001;
and PFS, 5.8 versus 6.3, P = 0.006).
IHC subtype and CTCs
The median OS and PFS were significantly different in HR+/
HER22 patients (n = 292) with ‡5 CTCs than in patients with
<5 CTCs (OS, 18.8 versus 48.7 months, P < 0.001; and PFS, 5.9
versus 7.1, P = 0.004) (Figures 2A and 3A).
In HER2+/HR+ patients with ‡5 CTCs, the median OS was
29.5 months versus not yet reached in patients with <5 CTCs
(P = 0.084) (Figure 2B). In HER2+/HR2 patients with ‡5
CTCs, the median OS was 27.2 versus 21.4 months in
patients with <5 CTCs (P = 0.991) (Figure 2C). In brief, the
hazard ratio of death in patients with ‡5 CTCs who had
undergone anti-HER2-targeted therapy did not significantly
differ from that of patients with <5 CTCs (Table 2). Also the PFS
among HER2+ groups was similar according the CTC count
(HER2+/HR+ patients PFS, 7.6 versus 8.6, P = 0.458; HER2+/
HR2 patients PFS, 6.9 versus 7.5, respectively, P = 0.719)
(Figure 3B and C).
Finally, among TN breast cancers (n = 124), patients with ‡5
CTCs had a median OS significantly shorter than patients with
<5 CTCs (10.4 versus 17.8 respectively, P = 0.001) (Figure 2D).
Median PFS was similar for TN breast cancer patients with ‡5
CTCs and patients with <5 CTCs (PFS, 5.1 versus 4.8,
respectively, P = 0.274) (Figure 3D).
The interaction test between the clinical outcomes and
subtypes was not significant for both PFS (P = 0.56) and OS
(P = 0.17).
Table 1. Patient characteristics by CTC count
Variable Overall No. of CTCs P value
<5 ‡5
All patients, n, % 517 100% 311 60.2% 206 30.8%
Median age (years) 49 49 49
Grade, N (%)
1 18 3.5 10 3.2 8 3.9
2 182 35.2 100 32.2 82 39.8
3 277 53.6 182 58.5 95 46.1
Unknown 40 7.7 19 6.1 21 10.2 0.061
HR+/HER22, N (%) 292 56.4 163 52.4 129 62.6 0.024
HR+/HER2+, N (%) 50 9.7 33 10.6 17 8.3 0.448
HR2/HER2+, N (%) 51 9.9 33 10.6 18 8.7 0.548
Triple negative, N (%) 124 24 82 26.4 42 20.4 0.141
Visceral metastasis, N (%) 319 61.7 188 60.5 131 63.6 0.518
Bone metastasis, N (%) 339 65.6 175 56.3 164 79.6 <0.001
Metastatic sites, N (%)
1 153 29.6 104 33.5 49 23.8
2 153 29.6 94 30.2 59 28.6
‡3 211 40.8 113 36.3 98 47.6 0.02
Line of therapy, N (%)
1 237 45.8 142 45.7 95 46.1
2 122 23.6 80 25.7 42 20.4
‡3 158 30.6 89 28.6 69 33.5 0.294
CTC, circulating tumor cell.
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multivariate analysis of predictors of PFS and OS
A multivariate Cox proportional hazards regression analysis
was carried out to determine the association between factors of
interest, PFS, and OS. In the backward stepwise Cox regressions
test, CTCs were predictors of both PFS and OS, considering
HR, HER2, visceral metastasis involvement, and number of
metastatic disease sites (Table 3). Patients with ‡5 CTCs had
a hazard of death of 2.08 (95% CI, 1.64–2.66; P < 0.001)
compared with those with <5 CTCs.
discussion
In this large retrospective study, we confirm the prognostic
value of assessing CTCs in MBC and provide a further
classification of prognostic groups. In the HR+/HER22
subgroup, patients had more frequently ‡5 CTCs (P = 0.024).
However, this finding is not concordant with results from
previously published reports using the CellSearch for CTC
enumeration in similar but smaller population of MBC patients
[10, 14, 16]. We showed that baseline CTCs enumeration had
Figure 1. (A) Overall survival (OS) and (B) progression-free survival (PFS) for all 517 patients, according to immunohistochemical subtype. HR+/HER22
in green (n = 292); HR+/HER2+ in purple (n = 50); HR2/HER2+ in light blue (n = 51); triple-receptor negative (TN) in red (n = 124). OS (C) and PFS (D)
for all 517 patients with <5 (blue) versus ‡5 (orange) circulating tumor cells (CTCs). Time was measured from basal blood draw to death for OS and to
radiologic evidence of disease progression (PFS).
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prognostic value in all breast cancer subtypes but appeared to be
most valuable in HR+ and TN breast cancers and least valuable
in HER2+ cancer treated with targeted therapy, suggesting an
interaction between CTCs and such therapies. Therefore, we
confirmed that in HR+/HER22 and TN breast cancers
subgroups, CTCs were a strong prognostic factor irrespective of
type and number of metastatic disease site.
HER2-targeted therapy combined with chemotherapy was
highly effective, regardless of CTC value, in patients with HER2+
primary tumors. We previously showed that the effect of
chemotherapy plus HER2-targeting drugs in patients with a high
baseline CTC count was considerable, with the number of CTCs
reduced to below the threshold of 5 in 16 of 17 (94%) subjects
[18]. Accordingly, other groups have shown that biological
therapies markedly decrease the number of CTCs at follow-up
CTC assays [14, 16]. In our study, HER2+MBC patients with ‡5
CTCs showed a PFS and OS similar to patients with <5 CTCs.
Since 84 of 101 HER2+ breast cancer patients received an anti-
HER2 treatment, we speculate that the high effectiveness of
trastuzumab and lapatinib may eliminate a predominant
population of circulating epithelial cells with HER2
amplification or overexpression thereby reducing the
prognostic value of CTCs enumeration. However, we should
state that the HER2+ group of patients is the smallest in
number among subtypes and that the interaction test between
subtypes and CTC count was negative. Moreover, tumor
specimens obtained before 1993 and the absence of primary
tumor gene expression profiling may lead to
a misclassification of breast cancer subtypes [28].
Our data confirm differences in overall prognosis among
different IHC subtypes. HER2+ breast cancer patients who
had received trastuzumab or lapatinib had the best overall
outcome, supporting the superior value of targeted therapy in
breast cancer. Several studies have shown that women with
luminal A, luminal B, and HER2 breast cancer subtypes [29]
have superior prognostic outcomes in the trastuzumab era to
those of women with TN tumors [30, 31]. The difference in
prognostic value tends to support the hypothesis that various
Figure 2. Overall survival (OS) in months according to immunohistochemical subtype and circulating tumor cell (CTC) value (patients with <5 CTCs in
blue versus ‡5 CTCs in orange). (A) HR+/HER22 (n = 292); (B) HER2+/HR+ (n = 50); (C) HER2+/HR2 (n = 51); (D) Triple-receptor negative (n = 124).
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initiating pathways of tumor progression underlie the clinical
heterogeneity and survival outcome of MBC subtypes and that
CTC detection and characterization will help us better
understand the biological behavior of tumor changes during
the metastatic process.
In conclusion, we provided for the first time, strong evidence
of a relationship between the IHC disease subtypes of breast
cancer, HER2-targeted therapy and CTC prognostic value in
MBC. These data suggest that breast cancer subtypes are
associated with strong differences in patterns of metastatic
Figure 3. Progression-free survival (PFS) in months according to immunohistochemical subtype and circulating tumor cell (CTC) value (patients with <5 CTCs
in blue versus ‡5 CTCs in orange). (A) HR+/HER22 (n = 292); (B) HER2+/HR+ (n = 50); (C) HER2+/HR2 (n = 51); (D) Triple-receptor negative (n = 124).
Table 2. Median OS duration (months) and hazard ratio of death (in favor of ‡5 CTCs) in all 101 HER2+ breast cancer patients, according to HR status
and treatment
Subtype N Median OS CTC < 5 Median OS CTC ‡ 5 Hazard ratio 95% CI P
HER2+/HR+ 50 N/A 29.5 2.18 0.88–5.37 0.092
HER2+/HR2 51 21.4 27.2 1.01 0.46–2.21 0.991
HER2+ treated with
anti-HER2 agents
84 40.5 29.5 1.4 0.73–2.7 0.315
N/A: median OS not yet reached. Anti-HER2 agents: trastuzumab or lapatinib. OS, overall survival; CTC, circulating tumor cell; HR, hormone receptor; CI,
confidence interval.
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spread. Moreover, we believe future therapeutic trials in MBC
should include CTC count to better stratify patients among
different prognostic groups.
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‡5 versus <5 CTCs 1.23 1.01–1.48 0.036 2.1 1.65–2.67 <0.001
HR (positive versus
negative)
0.76 0.62–0.92 0.006 0.49 0.38–0.63 <0.001
HER2 (positive versus
negative)
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